TY  - JOUR
T1  - MApping out biomarkers for alzheimer disease
AU  - Breteler MB
Y1  - 2011/01/19
N1  - 10.1001/jama.2010.2017
JO  - JAMA
SP  - 304
EP  - 305
VL  - 305
IS  - 3
N2  - 
The last decade has seen a surge in research in biomarkers for Alzheimer disease (AD) and other dementia disorders. With predictions of 1 in 4 persons ultimately developing the disease, disorders causing dementia have become one of the major health concerns in aging societies. Impending costs to society and individuals, as well as the enormous and increasing market potential to industry, make this an extremely important field in which the stakes, pressure, and expectations are high to develop better means to establish presence of disease, monitor progression, and make a diagnosis. In that arena, it is of the utmost importance that biomarkers are evaluated in a valid and rigorous way.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2010.2017
UR  - http://dx.doi.org/10.1001/jama.2010.2017
ER  -